Chinese CRO ShangPharma Moving Into Biologics, Small-scale Manufacturing To Broaden Customer Pool
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Limited-scale pharmaceutical manufacturing for research and biologics testing services are likely to become primary engines of expansion in the future for Chinese contract research organization ShangPharma, according to the Shanghai-based outfit's leadership